Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry's Off-Label Hearing Priorities Taking Shape

Executive Summary

Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.


Related Content

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Payers Want Access To US FDA's Pre-Submission Meetings
‘Who Is The Arbiter?’ US FDA Asks As It Mulls Loosening Off-Label Reins
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Off-Label Debate Between FDA, Industry To Formally Begin After Election
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts